Literature DB >> 35637615

Acceptance and commitment therapy for patient fatigue interference and caregiver burden in advanced gastrointestinal cancer: Results of a pilot randomized trial.

Catherine E Mosher1, Ekin Secinti1, Wei Wu1, Deborah A Kashy2, Kurt Kroenke3, Jonathan B Bricker4,5, Paul R Helft6, Anita A Turk6, Patrick J Loehrer6, Amikar Sehdev6, Ahmad A Al-Hader6, Victoria L Champion7, Shelley A Johns3,8.   

Abstract

BACKGROUND: Fatigue often interferes with functioning in patients with advanced cancer, resulting in increased family caregiver burden. Acceptance and commitment therapy, a promising intervention for cancer-related suffering, has rarely been applied to dyads coping with advanced cancer. AIM: To examine the feasibility, acceptability, and preliminary efficacy of acceptance and commitment therapy for patient-caregiver dyads coping with advanced gastrointestinal cancer. Primary outcomes were patient fatigue interference and caregiver burden.
DESIGN: In this pilot trial, dyads were randomized to six weekly sessions of telephone-delivered acceptance and commitment therapy or education/support, an attention control. Outcomes were assessed at baseline and at 2 weeks and 3 months post-intervention. SETTING/PARTICIPANTS: Forty patients with stage III-IV gastrointestinal cancer and fatigue interference and family caregivers with burden or distress were recruited from two oncology clinics and randomized.
RESULTS: The eligibility screening rate (54%) and retention rate (81% at 2 weeks post-intervention) demonstrated feasibility. At 2 weeks post-intervention, acceptance and commitment therapy participants reported high intervention helpfulness (mean = 4.25/5.00). Group differences in outcomes were not statistically significant. However, when examining within-group change, acceptance and commitment therapy patients showed moderate decline in fatigue interference at both follow-ups, whereas education/support patients did not show improvement at either follow-up. Acceptance and commitment therapy caregivers showed medium decline in burden at 2 weeks that was not sustained at 3 months, whereas education/support caregivers showed little change in burden.
CONCLUSIONS: Acceptance and commitment therapy showed strong feasibility, acceptability, and promise and warrants further testing. TRIAL REGISTRATION: ClinicalTrials.gov NCT04010227. Registered 8 July 2019, https://clinicaltrials.gov/ct2/show/NCT04010227?term=catherine+mosher&draw=2&rank=1.

Entities:  

Keywords:  Neoplasms; acceptance and commitment therapy; caregiver burden; clinical trial; family caregivers; fatigue; quality of life

Mesh:

Year:  2022        PMID: 35637615      PMCID: PMC9396957          DOI: 10.1177/02692163221099610

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   5.713


  62 in total

1.  Depression, cytokines, and pancreatic cancer.

Authors:  William Breitbart; Barry Rosenfeld; Kristen Tobias; Hayley Pessin; Geoffrey Y Ku; Jianda Yuan; Jedd Wolchok
Journal:  Psychooncology       Date:  2013-10-18       Impact factor: 3.894

2.  Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments.

Authors:  Daniel J Buysse; Lan Yu; Douglas E Moul; Anne Germain; Angela Stover; Nathan E Dodds; Kelly L Johnston; Melissa A Shablesky-Cade; Paul A Pilkonis
Journal:  Sleep       Date:  2010-06       Impact factor: 5.849

3.  Examining the role of subjective and objective burden in carer health-related quality of life: the case of colorectal cancer.

Authors:  Paul Hanly; Rebecca Maguire; Philip Hyland; Linda Sharp
Journal:  Support Care Cancer       Date:  2014-12-12       Impact factor: 3.603

4.  Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing.

Authors:  Elizabeth A Hahn; Robert F Devellis; Rita K Bode; Sofia F Garcia; Liana D Castel; Susan V Eisen; Hayden B Bosworth; Allen W Heinemann; Nan Rothrock; David Cella
Journal:  Qual Life Res       Date:  2010-04-25       Impact factor: 4.147

5.  Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

Authors:  D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman
Journal:  Qual Life Res       Date:  1998-05       Impact factor: 4.147

6.  Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial.

Authors:  Laura S Porter; Francis J Keefe; Donald H Baucom; Herbert Hurwitz; Barry Moser; Emily Patterson; Hong Jin Kim
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

7.  Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: results of a randomized pilot trial.

Authors:  Hoda Badr; Cardinale B Smith; Nathan E Goldstein; Jorge E Gomez; William H Redd
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

8.  Symptom prevalence in lung and colorectal cancer patients.

Authors:  Anne M Walling; Jane C Weeks; Katherine L Kahn; Diana Tisnado; Nancy L Keating; Sydney M Dy; Neeraj K Arora; Jennifer W Mack; Philip M Pantoja; Jennifer L Malin
Journal:  J Pain Symptom Manage       Date:  2014-06-26       Impact factor: 3.612

9.  Acceptance and commitment therapy for fatigue interference in advanced gastrointestinal cancer and caregiver burden: protocol of a pilot randomized controlled trial.

Authors:  Catherine E Mosher; Ekin Secinti; Kurt Kroenke; Paul R Helft; Anita A Turk; Patrick J Loehrer; Amikar Sehdev; Ahmad A Al-Hader; Victoria L Champion; Shelley A Johns
Journal:  Pilot Feasibility Stud       Date:  2021-04-20

10.  The Challenges of Enrollment and Retention: A Systematic Review of Psychosocial Behavioral Interventions for Patients With Cancer and Their Family Caregivers.

Authors:  Lixin Song; Yousef Qan'ir; Ting Guan; Peiran Guo; Shenmeng Xu; Ahrang Jung; Eno Idiagbonya; Fengyu Song; Erin Elizabeth Kent
Journal:  J Pain Symptom Manage       Date:  2021-04-30       Impact factor: 5.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.